GHRH and Pituitary GH Regulation
Growth hormone-releasing hormone (GHRH) is a 44-amino-acid hypothalamic peptide that acts as the primary driver of pulsatile growth hormone (GH) secretion from anterior pituitary somatotrophs. GHRH binds the GHRH receptor (GHRHR), a class B G-protein-coupled receptor that signals through Gαs/cAMP/PKA to stimulate GH synthesis and release.Native GHRH(1–44) has a plasma half-life of under 5 minutes, rapidly cleaved at the Ala²-position by dipeptidyl peptidase IV (DPP-IV) and at other sites by serum proteases. This rapid clearance makes native GHRH impractical for most research designs beyond acute stimulation tests. Three synthetic analogs have been developed to extend GHRH's plasma durability for extended research protocols: sermorelin, CJC-1295, and tesamorelin.
The Three Analogs: Structural Strategy Matrix
| Property | Sermorelin | CJC-1295 (No DAC) | CJC-1295 (DAC) | Tesamorelin |
| GHRH sequence | 1–29 | 1–29 | 1–29 | 1–44 (full) |
| Modification type | Truncation | Ala²→D-Ala, others | Ala²→D-Ala + C8 fatty acid | N-term trans-3-hexenoic acid |
| DPP-IV resistance | Partial (truncated at cleavage site) | Strong (Ala²→D-Ala) | Strong | Strong (N-term conjugate blocks cleavage) |
| Albumin binding | None | None | Yes (via DAC) | Weak (C6 fatty acid) |
| Plasma half-life | ~10–20 min | ~30 min | ~6–8 days | ~26 min |
| GH pulse shape | Short, closely mimics native | Intermediate | Extended, non-pulsatile | Intermediate |
| GHRHR sequence | Partial (1-29) | Partial (1-29) | Partial (1-29) | Full (1-44) |
| Clinical research status | Phase 3 completed | Investigational | Investigational | FDA-approved (HIV-LD) |
Individual Compound Profiles
Sermorelin — Native 1–29 Sequence, Minimal Modification
Sermorelin uses residues 1–29 of human GHRH without any amino-acid modification. The half-life extension relative to native GHRH(1–44) comes from truncation: the first 29 residues retain full GHRHR agonist activity, and the natural DPP-IV cleavage site at Ala² is still present — but without the C-terminal extension, the metabolic landscape is somewhat different.
Sermorelin's primary research utility is providing the closest functional analog to native GHRH pulsatility available as a stable research compound: it produces short GH pulses of approximately physiological amplitude and duration, which is the preferred model for studies examining pituitary somatotroph responsiveness, GH pulsatility, or long-term axis stimulation in aging or growth hormone deficiency models.
CJC-1295 (No DAC) — Stabilized 1–29 with Extended Half-Life
CJC-1295 without DAC uses the 1–29 sequence with targeted amino-acid substitutions — most importantly Ala²→D-Ala, which eliminates the primary DPP-IV cleavage site. Additional modifications increase GHRHR binding affinity at several positions along the N-terminal domain. Together, these changes extend the plasma half-life to approximately 30 minutes without albumin binding.
CJC-1295 No DAC occupies the mechanistic space between sermorelin (very short) and CJC-1295 DAC (very long): it produces GH pulses that are longer in duration than sermorelin but still return to baseline — preserving a pulsatile profile suitable for studies where GHRH analog duration and GHRP synergy are research variables.
CJC-1295 (with DAC) — Sustained, Non-Pulsatile GH Elevation
CJC-1295 with Drug Affinity Complex (DAC) adds a C8 fatty acid conjugated to Lys³⁸ via a maleimide-based linker, enabling binding to serum albumin in a manner that creates a large plasma reservoir. The resulting half-life (~6–8 days) means that GH levels are sustained well above baseline continuously rather than pulsing — a fundamentally different GH stimulation profile.
CJC-1295 DAC is the preferred tool when sustained, tonic GH elevation is the experimental objective, rather than pulsatile physiology. Research designs using CJC-1295 DAC should account for the fact that sustained GH elevation suppresses pituitary sensitivity over time and does not replicate the pulsatile dynamic that characterizes normal physiological GH secretion.
→ CJC-1295 & Ipamorelin research primer
Tesamorelin — Full 44-aa Sequence with Fatty Acid Stabilization
Tesamorelin retains the complete 44-residue GHRH sequence with trans-3-hexenoic acid conjugated to the N-terminus. This approach provides DPP-IV resistance through steric blocking of the cleavage site rather than amino-acid substitution, while preserving the full GHRHR binding interface.
The full-sequence advantage: published receptor-binding affinity data suggests more complete GHRHR occupation than truncated 1–29 analogs. The intermediate half-life (~26 min) preserves pulsatile GH dynamics similar to CJC-1295 No DAC, while the extensive published clinical dataset (Phase 3 trials, FDA approval for HIV-associated lipodystrophy) provides unusually rich reference pharmacokinetics and pharmacodynamic endpoints for a GHRH analog.
Selecting the Right GHRH Analog: Research Decision Framework
Research question: What does pulsatile GHRH stimulation produce in a given model?Use sermorelin. Shortest half-life, most physiological pulse shape, no albumin binding to complicate pharmacokinetics.
Research question: How does GHRH analog half-life affect GH pulse amplitude and downstream signaling?Use sermorelin vs CJC-1295 No DAC as a half-life comparison pair. Single-variable difference: plasma durability.
Research question: What does sustained (non-pulsatile) GH axis activation produce?Use CJC-1295 DAC. The multi-day half-life produces continuous GH elevation for sustained-stimulus experimental designs.
Research question: How does the complete GHRH sequence vs the truncated 1–29 fragment affect receptor engagement?Use tesamorelin vs sermorelin or CJC-1295 No DAC. The key difference is sequence completeness vs truncation.
Research question: How does GHRH receptor activation interact with ghrelin receptor (GHS-R) activation?Pair any GHRH analog with a GHRP (ipamorelin, GHRP-6, GHRP-2). The two receptor axes are synergistic on pituitary GH release. CJC-1295 + ipamorelin is the most extensively published combination; sermorelin + ipamorelin is also common. See the CJC-1295 & Ipamorelin research primer for the combination framework.
Shared Mechanistic Features
All three GHRH analogs share the core mechanism: binding and activating GHRHR on anterior pituitary somatotroph cells → Gαs coupling → adenylyl cyclase activation → ↑cAMP → PKA activation → GH synthesis and secretion.
Key shared constraints:
- Pituitary-dependent: All GHRH analogs require functional somatotroph cells. In pituitary damage or ablation models, GHRH analogs will not drive GH secretion
- Somatostatin opposition: Hypothalamic somatostatin tonically inhibits GH release; GHRH analogs do not block somatostatin and their efficacy is attenuated by high somatostatin tone
- Feedback-regulated: Sustained GH elevation feeds back to suppress GHRHR expression — a factor in research designs that use long-term or high-dose protocols
Laboratory Handling Notes
All three are supplied as lyophilized powders. Reconstitute in bacteriostatic water following standard protocols. Sermorelin and CJC-1295 No DAC reconstitute cleanly; CJC-1295 DAC and tesamorelin may require slightly longer mixing due to their fatty acid conjugates. Store lyophilized at −20 °C; reconstituted at 2–8 °C. See the reconstitution guide for standard workflow.
Q: Why does CJC-1295 with DAC produce non-pulsatile GH rather than large pulses?The ~6–8 day half-life means receptor occupancy is continuous — somatotrophs are chronically stimulated rather than stimulated in pulses. This produces tonic GH elevation rather than the discrete pulses seen with short-acting analogs. Chronic somatotroph stimulation also leads to GH receptor downregulation and altered downstream IGF-1 kinetics relative to pulsatile stimulation — a key distinction for research designs that care about the pulsatile vs tonic GH stimulation distinction.
Q: Can GHRH analogs be used without a GHRP co-treatment?Yes — GHRH analogs produce GH secretion as monotherapy. The GHRP combination amplifies GH pulse amplitude synergistically (the two axes — GHRH and ghrelin — converge on the same somatotroph output). Many published research designs use GHRH analogs alone to probe the GHRH axis specifically. Combination protocols are used when maximum GH stimulation or pulsatile amplitude modeling is the objective.
Q: What is the published pharmacodynamic difference between the full 44-aa GHRH sequence (tesamorelin) and the 1-29 fragment?The C-terminal residues (30–44) contribute to the GHRHR binding interface and are associated with slightly higher receptor affinity for the full-length sequence in published receptor pharmacology studies. However, the primary GH secretagogue activity — measured as GH pulse area under the curve — is largely preserved in the 1–29 fragment. The clinical significance of the affinity difference in research models depends on receptor expression levels, assay sensitivity, and study design.
See Also
- Peptide Half-Life Reference — compiled pharmacokinetic data including all three GHRH analogs
- GHRP Comparison — complementary GHRPs studied in combination with GHRH analogs
- Ipamorelin Research Primer — dedicated primer on ipamorelin for GHRH combination research
Research Compound Availability
The GHRH analogs discussed in this overview are available for laboratory research. Browse lot-specific batch documentation for each:
All Phase 1 Peptides products are supplied exclusively for laboratory research and in vitro studies. They are not intended for human or animal consumption, clinical use, or therapeutic application.